Phase 3 Ixo-Vec Program Advances - Takeaways - MDSpire

Phase 3 Ixo-Vec Program Advances

  • By

  • Jim Gallagher, senior managing editor

  • May 14, 2026

  • 4 min

Share

  • 1

    The phase 3 program for ixo-vec in neovascular AMD includes ARTEMIS and AQUARIUS studies evaluating its long-term efficacy.

  • 2

    Ixo-vec aims to provide continuous aflibercept production after a single injection, reducing treatment burden for nAMD patients.

  • 3

    Previous trials, OPTIC and LUNA, showed sustained aflibercept expression and stable visual acuity with reduced injection frequency.

  • 4

    Safety findings indicated no severe adverse events, with mild inflammation manageable through local corticosteroids.

  • 5

    Data from ARTEMIS is expected in early 2027, with AQUARIUS results anticipated later that year.

Original Source(s)

Phase 3 Ixo-Vec Program Advances

  • by Jim Gallagher, senior managing editor

  • May 14, 2026

Related Content

Optical coherence tomography measurement of retinal layers above the peripapillary hyperreflective ovoid mass-like structure in true papilloedema and pseudo-papilloedema

Accidental intravitreal injection of a veterinary inactivated FMD vaccine resulting in noninfectious intraocular inflammation: a case report

Accelerating Peer Learning in Eye Care

Lumenis launches peer-to-peer learning program aimed at developing practical strategies for modern-day practice

  • May 27, 2026

  • 2 min